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Abstract
Perioperative ischemia is a frequent event in patients undergoing major non-cardiac vascular or
general surgery. This is in agreement with clinical, pathophysiological, and epidemiological evidence
and constitutes an additional diagnostic therapeutic factor in the assessment of these patients. Form
a clinical standpoint, it is well known that multidistrict disease, especially at the coronary level, is a
severe aggravation of the operative risk. From a pathophysiological point of view, however, surgery
creates conditions able to unmask coronary artery disease. Prolonged hypotension, hemorrhages,
and haemodynamic stresses caused by aortic clamping and unclamping during major vascular
surgery are the most relevant factors endangering the coronary circulation with critical stenoses.
From the epidemiological standpoint, coronary disease is known to be the leading cause of
perioperative mortality and morbidity following vascular and general surgery: The diagnostic
therapeutic corollary of these considerations is that coronary artery disease – and therefore the
perioperative risk – in these patients has to be identified in an effective way preoperatively.
Background
Risk stratification before major vascular surgery is an eve-
ryday challenge for the clinical cardiologist. The predic-
tion of events in this set of patients bears important
implications, epidemiological, clinical and practical. In
fact, the size of the problem is not negligible. Cardiovas-
cular complications account for approximately half of all
mortality after non cardiac surgery and are the leading
cause of death in those patients [1]. Moreover, patients
with peripheral vascular artery disease have a higher
chance of dying for cardiac and cardiovascular causes
compared to patients with no peripheral vessel disease
[2]. When both severe and symptomatic peripheral vascu-
lar disease were present, the risk of death due to coronary
artery disease was 10 to 15 times higher [2]. In this set of
patients the incidence of hard cardiac events (myocardial
infarction and death) in the post-operative period is
higher when compared to other type of non cardiac sur-
gery. These patients are not only at risk for perioperative
events, but they are also subject to late hard cardiac events.
The need of an effective risk stratification is to select
patients in order to face safely the surgical procedure, by
balancing the benefit of each procedure with the inherent
risks. Once the aim of risk stratification is stated, i.e. the
identification of patients with a high probability of expe-
riencing a hard cardiac event, the criteria of selection have
to be discussed.
Risk stratification: which patients?
The lack of controlled and randomized trials designed to
assess the best strategy of stratification for patient evalua-
tion before major vascular non cardiac surgery brought to
the definition of guidelines by the American Heart
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Association/American College of Cardiology [3]with the
aim of: 1 – identify patients at extremely high risk in
whom surgery should be canceled, or other less hazardous
procedures should be considered; 2 – identify those
patients in whom the optimization of medical therapy or
a coronary revascularization before surgery might reduce
the risk of the surgical procedure; 3 – identify those
patients in whom an invasive and intensive monitoring
might reduce the risk of perioperative events; 4 – assess
the long-term risk of a future cardiac event. The available
data of the literature show that clinical models of stratifi-
cation in patients undergoing major vascular non cardiac
surgery have a relatively low prognostic power [4,5].
Nonetheless, it is a rational approach to avoid any form of
risk stratification in asymptomatic patients with no his-
tory of coronary artery disease. On the other side patients
with peripheral artery disease do not have this clear clini-
cal presentation and might experience cardiac complica-
tions due to several reasons: 1 – many of the risk factors
contributing to peripheral vascular disease (diabetes mel-
litus, smoking habit, dyslipidemia) are also risk factors for
coronary artery disease; 2 – the usual symptomatic presen-
tation for coronary artery disease in these patients may be
obscured by exercise limitations due to advanced age or
intermittent claudication; 3 – major arterial operations
often are time-consuming and may be associated with
substantial fluctuations in intra-extra vascular fluid vol-
umes, blood pressure, heart rate. These considerations do
not imply that all patients undergoing major vascular sur-
gery should undergo risk stratification. The decision to
recommend further stratification procedures in each sin-
gle patient must take into account the probability of effi-
cacy versus the potential risks. It is conceivable that during
the stratification process the risks of tests or treatment
might outweigh the potential benefits of the evaluation.
Keeping in mind that the incidence of coronary artery dis-
ease in patients with peripheral vascular disease is around
60% and asymptomatic [6], preoperative screening might
represent the first one for the assessment of a previously
unsuspected coronary artery disease. Therefore, many
patients will have their coronary artery disease diagnosed
at the moment of the intervention whereas those with
known coronary artery disease will benefit of an optimi-
zation of the medical regimen.
Surgical risk
In the preoperative stratification the estimate of the sur-
gery-specific risk is a relevant one. In fact, a patient under-
going laparoscopic surgery should be treated very
differently from a patient undergoing vascular surgery.
Vascular surgery with its high likelihood of underlying
coronary artery disease and its high degree of hemody-
namic cardiac stress with profound alterations in heart
rate, blood pressure, vascular volume, bleeding, clotting
tendencies represent an intermediate (1–5%) to high risk
(>5%) [3] (Table ) procedure.
Risk stratification: Clinical evaluation
The assessment of the patient's clinical status should com-
prise the first step of risk stratification. As already stated,
literature provides a wide range of clinical models for the
prediction of preoperative risk. The prototype of all mod-
els is the one developed by Goldman [4]which correlates
clinical variables with post-operative cardiac events. In a
multivariate analysis, nine parameters were found to be
independent predictors of cardiac events. This analysis
was used to develop a point system that could be used to
predict risk. Progression from class I (lowest risk) to class
IV (highest risk) was associated with an incremental
increase in the percentage of patients with cardiac compli-
Table 1: Clinical risk stratification for nonsurgical procedures
High (>5%)
Emergent major operations
Aortic and other major vascular
Peripheral vascular
Anticipated prolonged surgical procedures associated with large fluid shifts and/or blood loss
Intermediate (<5%)
Carotid endarterectomy
Head and neck
Intraperitoneal and intrathoracic
Orthopedic
Prostate
Low (<1%)
Endoscopic procedures
Superficial procedure
Cataract
Breast
Modified from [3]Cardiovascular Ultrasound 2004, 2 http://www.cardiovascularultrasound.com/content/2/1/4
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cations or cardiac death. Despite successful risk stratifica-
tion in a general surgical population, the Goldman study
has been criticized for the lack of considerations of cardiac
symptoms. To this aim Detsky et al. [5] developed a
model similar to the previous but more focused on car-
diac symptoms. It also differed form Goldman's model in
the use of the score for a Bayesan analysis to provide a post
test probability of events. The AHA/ACC guidelines iden-
tify several clinical predictors of risk, in a severity scale
(Table 2), without providing a modeling of clinical strati-
fication. Although, risk indexes have an important role in
the patient's clinical evaluation, the presence of myocar-
dial ischemia might be offset particularly in patients with
peripheral vascular disease. Thus, risk classification based
exclusively on clinical grounds may not prove to be as
helpful when applied to vascular surgery patients [7].
AHA/ACC [3] guidelines suggest a shortcut approach to a
large number of patients in whom the decision to recom-
mend testing before surgery can be difficult (Table 3).
Basically, if 2 of the 3 listed factors are true, the guidelines
suggest the use of noninvasive cardiac testing as part of the
preoperative evaluation. AHA/ACC guidelines recom-
mend that no further cardiac evaluation is required if a
recent (within 2 years) coronary angiogram failed to
reveal the presence of significant obstructive coronary
artery disease, or if bypass surgery was performed within
the preceding 5 years, in the absence of anginal symptoms
[3].
Risk stratification: which test is best?
Once, according to clinical variables, an intermediate to
high risk of perioperative events is recognized for the indi-
vidual patient it will be necessary to establish the pres-
ence, extent and severity of inducible myocardial
ischemia, parameters which correlate with short and long-
term prognosis in patients undergoing major vascular non
cardiac surgery. Risk stratification with exercise electrocar-
diography has been performed [8-16], but this type of
testing is not suitable for patients with peripheral vascular
disease due to their inability to reach an ischemic thresh-
old. Cutler et al. [9] demonstrated that patient who
achieved >75% of maximum predicted heart rate and no
ischemic electrocardiographic modifications did not
develop postoperative cardiac complications, whereas
there were 10 postoperative cardiac events, including 7
myocardial infarctions (25%), in the high risk group.
Table 2: Clinical predictors of increased perioperative cardiovascular risk
Major
Recent myocardial infarction (<30d)
Unstable or severe angina
Decompensated congestive heart failure
High-grade atrioventricular block
Symptomatic ventricular arrhythmias in the presence of underlying heart disease
Supraventricular arrhythmias with uncontrolled ventricular rate
Severe valvular disease
Intermediate
Mild angina pectoris
Prior myocardial infarction by history or pathological Q waves
Compensated or prior congestive heart failure
Diabetes mellitus
Minor
Advanced age
Abnormal ECG
Rhythm other than sinus
Low functional capacity
History of stroke
Uncontrolled systemic hypertension
Modified from [3]
Table 3: Shortcut to noninvasive testing in preoperative if any two factors are present
1. Intermediate clinical predictors are present (Canadian class 1 or 2 angina, prior MI based on history or pathologic Q waves, compensated or 
prior heart failure, diabetes, or renal insufficiency)
2. Poor functional capacity (less than 4 METs)
3. High surgical risk procedure (aortic repair or peripheral vascular surgery; prolonged surgical procedures with large fluid shifts or blood loss)Cardiovascular Ultrasound 2004, 2 http://www.cardiovascularultrasound.com/content/2/1/4
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Other authors [15] have confirmed these data by showing
that the failure to achieve 85% of maximum predicted
heart rate or 5 metabolic equivalents is a predictor of poor
outcome in vascular surgery patients. These data, consist-
ently with the AHA/ACC guidelines stress the need for an
adequate functional capacity to select high risk patients.
Pharmacologic stress testing with perfusion scintigraphy
or ultrasound, alternative to exercise is more suitable in
this set of patients due to the aforementioned physical
limitations. Myocardial perfusion imaging with dipyrida-
mole has been used widely for the preoperative evaluation
of patients before vascular surgery [17-24]. The positive
predictive value of thallium redistribution ranged from
4% to 20% in reports that included >100 patients, but
more recent studies have further reduced the positive pre-
dictive value of this method, likely due to the selection of
high risk patients for whom an alternative approach is fol-
lowed (coronary revascularization before peripheral sur-
gery, optimization of medical regimen etc.). The negative
predictive value of a normal scan remains high at 99% for
myocardial infarction and/or cardiac death. Some studies
have demonstrated that not only the presence but the
magnitude and severity of the perfusion abnormalities
correlated with a worse outcome, suggesting that more
severe defects have a greater cardiac risk [22,23,25]. The
meta-analysis by Shaw et al. [26] analyzed the results of
10 articles describing the use of dipyridamole-thallium in
vascular surgery candidates over a 9-year period (1985–
1994). Cardiac death or nonfatal myocardial infarction
occurred in 1, 7, and 9% of patients with normal results,
fixed defects, and reversible defects on thallium scans,
respectively. Moreover, 3 out of the 10 studies analyzed
have used a semi-quantitative scoring demonstrating a
higher incidence of cardiac events in patients with two or
more reversible defects [26]. Recently Baron et al [27],
raised the need for caution in routine screening with dipy-
ridamole thallium stress test of all patients before vascular
surgery. In this review of 457 patients undergoing elective
abdominal aortic surgery, the presence of definite coro-
nary artery disease and age greater than 65 years were bet-
ter predictors of cardiac complications than perfusion
imaging. In line with this evidence, Mangano [24] reas-
sessing the use of perfusion scintigraphy, has shown its
poor specificity mostly when applied to consecutive and
unselected patients. In consideration of these data, some
authors have stressed the need to select patients on clini-
cal grounds first to obtain a better power of stratification
when imaging techniques are used [7,17,28].
Many reports have demonstrated that pharmacological
stress echocardiographic imaging techniques predict peri-
operative ischemic events in patients undergoing noncar-
diac vascular surgery [29-36]. The experience of several
groups with either dobutamine or dipyridamole indicates,
in univocal terms, that these tests have a very high nega-
tive predictive value (between 90 and 100%): a negative
test is associated with a very low incidence of cardiac
events and allows a safe surgical procedure. Much lower is
the positive predictive value (between 25 and 45%). In
the series by Poldermans et al. [32] the presence of a new
wall motion abnormality was a powerful determinant of
an increased risk for perioperative events after multivari-
ate adjustment for different clinical and echocardio-
graphic variables. In an update of the EPIC (Echo
Persantine International Cooperative) Study – subproject
risk stratification in major noncardiac vascular surgery, in
a patient population of 509 [37] it has been demonstrated
that test positivity identified as the variation between rest
and stress wall motion score index (delta peak wall
motion score) was the best predictor of peri-operative in-
hospital cardiac death. When the data were analyzed
according to an interactive procedure, considering the var-
iables in clinical order: historical parameters first, preop-
erative risk assessed on clinical grounds and stress echo
parameters; still stress echocardiographic parameters
added significant prediction to the model compared with
historical and clinical variables. Published data, although
less numerous than for perfusion scintigraphy, show that
pharmacologic stress echocardiography is safe and effec-
tive in the risk stratification of this set of patients. In a
meta-analysis of 15 studies [26] comparing intravenous
dipyridamole-Thallium-201 imaging and dobutamine
echocardiography for risk stratification before vascular
surgery it has been demonstrated that the prognostic value
of noninvasive stress imaging abnormalities for perioper-
ative ischemic events is comparable between available
techniques but that the accuracy varies with coronary
artery disease prevalence (fig. 2). One study compares
dipyridamole perfusion scintigraphy with dipyridamole
stress echocardiography for the prediction of periopera-
tive cardiac events [38]. Sensitivity of the two techniques
is not significantly different (scintigraphy vs. stress echo,
90% vs.68%, p = ns), while specificity as well as diagnostic
accuracy are significantly better for stress echocardiogra-
phy (88% vs. 68%, p < 0.001 and 84% vs. 72%, p = 0.02,
respectively).
In a recent meta-analysis Kertai et al. [39] showed that
pharmacologic stress echocardiography with dobutamine
or dipyridamole is significantly better than perfusion scin-
tigraphy in the prediction of perioperative events OR 37.1
(95% CI, 8.1 – 170.1) vs. 9.6 (95% CI 4.9 – 18.4, P = 0.12,
dipyridamole vs. dobutamine) vs scintigraphy (OR 1.95
(95% CI, 1.2 – 3.2). On the basis of these data stress
echocardiography has a prognostic profile comparable to
perfusion scintigraphy, if not better. But these
considerations should be put into a wider framework in
the clinical decision making. In fact, medical imaging
with nuclear techniques represents the main manmade
source of radiations and its environmental impact shouldCardiovascular Ultrasound 2004, 2 http://www.cardiovascularultrasound.com/content/2/1/4
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be considered along with the individual risk of each single
patient of experiencing a fatal or non-fatal cancer" [40].
On this issue a European Law states that a nuclear exami-
nation can be performed only when "it cannot be replaced
by other techniques which do not employ ionizing radia-
tions. This is one of those cases in which the nuclear tech-
nique can be clearly replaced without loss of critical
information.
Risk stratification: Instructions for use
Once, on the basis of clinical and stress testing parame-
ters, a patient has been recognized at high risk for future
cardiac events, how to translate this information in clini-
cal practice? In case of pharmacologic stress test negativ-
ity, because of its high negative predictive value, the
surgical procedure might be undertaken safely. In case of
test positivity different factors have to be taken into con-
sideration. The stress echo response should not be read as
a yes or not gate-keeper to vascular surgery. In fact, a stress
echo response has different shades of severity, taking into
consideration the time of appearance of the wall motion
abnormalities (the shorter the time the higher the proba-
bility of an extensive coronary artery disease), the extent
of wall motion abnormalities (a high number of the seg-
ments is related to an extensive disease), and the severity
of the inducible dyssynergy [41]. For dobutamine stress
echocardiography the need to reach the target heart rate is
another critical parameter for the stratification of the
stress echo response [42].
Therefore, on the basis of these parameters, it is possible
to grade the response and consequently the therapeutic
approach to the patient, which is different from case to
case since patients with a high risk stress echo result
should undergo coronary angiography and postpone car-
diac surgery. Many studies have investigated the need for
a coronary revascularization before a noncardiac one, but
there is no study addressing this issue prospectively and
evaluating the impact of a prophylactic coronary revascu-
larization on peri-operative or long-term morbidity and
mortality. Retrospective studies have demonstrated that
patients undergoing coronary bypass surgery have a low
rate of mortality when undergoing noncardiac surgical
procedures [43,44]. In a sub-analysis of data from the
Coronary Artery Surgery Study [43] it has been demon-
strated that in 3368 patients undergoing urologic, ortho-
pedic, breast and skin surgery the mortality rate was lower
than 1% independently of a previous coronary revascular-
ization. However, patients undergoing thoracic abdomi-
nal, vascular and head and neck surgery had a risk for
death or myocardial infarction significantly higher in the
first 30 days from surgery. In this set of patients undergo-
ing high risk surgical procedures, a previous coronary
revascularization reduced the incidence rate of death
(1.7% vs. 3.3%, p = 0.03, revascularized vs. non-revascu-
larized). Therefore, in assessing the risks and benefits of
perioperative intervention strategy, risks associated with
non-cardiac surgery must be individualized. In selected
patient populations at very high risk, coronary revascular-
ization should be taken into consideration, weighing the
potential risk reduction with the additional one associ-
ated with cardiac surgery and evaluating the long-term
implications of severe forms of coronary artery disease.
Percutaneous revascularization procedures are a possible,
when suitable, alternative with no clear evidence of their
prognostic impact. Given the limited data, the indications
for PTCA in the preoperative setting are identical to those
developed by AHA/ACC guidelines for the use of PTCA in
general [45]. Nonetheless, this type of revascularization
raise several practical problems for patient management.
Stent thrombosis remains a very morbid event resulting in
MI or death in the majority of patients in whom it occurs
and related to the need to suspend antiplatelet treatment
before surgery in order to avoid intraoperatory bleeding
[46]. Therefore, It appears reasonable to delay elective
non-cardiac surgery for two weeks and ideally 4 weeks to
allow for at least partial endothelization of the stent, but
not for more than 6 weeks or 8 weeks, when restenosis
begins to occur (if it is to occur) [3].
In case of a less severe stress echo response (small extent
of ischemia and/or high dose positivity), it does not seem
to be necessary surgery cancellation, but a more aggressive
medical approach is warranted. Recent data show, the
benefit associated with the use of beta-blockers in the
postoperative period. Poldermans et al. have demon-
strated that bisoprolol reduces the perioperative incidence
of death from cardiac causes 3.4% vs. 17%; bisoprolol vs.
placebo; p = 0.02) and nonfatal myocardial infarction
(0% vs. 17%; bisoprolol vs. placebo; P < 0.001) in high
risk patients (dobutamine stress echocardiography posi-
tivity) undergoing major vascular surgery [47]. Subse-
quently, the total cohort of the study was reanalyzed,
including those patients with no inducible ischemia at
dobutamine stress echocardiography, showing that
patients who had fewer than 3 clinical risk factors and tak-
ing beta-blockers had a lower risk of cardiac complica-
tions compared with those not taking beta-blockers (0.8%
vs. 2.3%). In patients with 3 or more risk factors, those
taking beta-blockers who had a dobutamine stress
echocardiography demonstrating 4 or fewer segments of
new wall motion abnormalities had a significantly lower
incidence of cardiac complications (2.3% vs 10.6%).
Among patients with more extensive ischemia on dob-
utamine stress echocardiography (5 or more segments),
beta-blocking therapy did not offer protection for
cardiovascular events [48]. The protective effect of beta-
blocking therapy is persistent in the long-term follow-up
[49,50].Cardiovascular Ultrasound 2004, 2 http://www.cardiovascularultrasound.com/content/2/1/4
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Conclusions
In conclusion, not all patients should undergo risk strati-
fication. The decision to recommend further testing for
the individual patient has to take into consideration the
estimated probabilities of effectiveness versus risk. It is
possible that in the stratification process, the risks from
the tests and treatments may offset the potential benefit of
evaluation. Resources should be directed away from the
unnecessary investigation of low risk individuals, towards
improved perioperative management for those at high
risk. Pharmacologic stress echocardiography appears to be
a versatile tool in this set of patients and its use is war-
ranted. No major technical advances have been made in
order to reduce the inter-observer variability of the tech-
nique strictly linked to operator's experience but the
search for an objective, operator-independent assessment
of ischemia is on the run [51]. To date, in the absence of
prospective randomized trials, it appears reasonable to
perform coronary revascularization before peripheral vas-
cular surgery, in the presence of a markedly positive result
of stress echo, and reserve only for those in whom it
would be considered appropriate as part of their routine
long-term care, and to adopt a more conservative
approach – with a watchful cardiological surveillance cou-
pled with through pharmacological protection – in
patients with less severe ischemic responses during stress
[52].
Univariate hazard ratio for intravenous dipyridamole-thalium-201 myocardial perfusion, dobutamine stress echocardiography  and dipyridamole stress echocardiography for each of the published reports (redrawn and updated from [26]) Figure 1
Univariate hazard ratio for intravenous dipyridamole-thalium-201 myocardial perfusion, dobutamine stress echocardiography 
and dipyridamole stress echocardiography for each of the published reports (redrawn and updated from [26]).
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